Clinical Trials Browser

Phase 3 × Recruiting × Fallopian Tube Neoplasms × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

770 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

580 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

500 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

520 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05659381 2025-12-24

HOTT

Phase 3 Recruiting

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04111978 2025-09-29

MATAO

Phase 3 Recruiting

540 enrolled

Gynecologic

Fallopian Tube Neoplasms, Peritoneal Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06834672 2025-04-13

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Recruiting

450 enrolled

Gynecologic

Fallopian Tube Neoplasms